Anemia of moderate to severe intensity is almost invariably present in patients with chronic renal failure (CRF) requiring maintenance hemodialysis; and a substantial number of patients need transfusions to alleviate symptoms caused by their anemia.
The anemia in most patients is multifactorial. The primary cause is an inability of the marrow to produce an adequate number of red cells (1) . This defect in erythropoiesis becomes more significant because of a decrease in the life span of erythrocytes in uremic plasma. It should be noted that the shortened red cell life span of uremic patients is usually mild enough that a normally functioning erythron would be able to compensate for it.
The primary reason for the decrease in the rate of erythropoiesis is the inability of the diseased kidneys to produce the required amount of erythropoietin in response to alterations in their oxygen supply (1) . Extra renal sites of erythropoietin production, thought to reside in the liver (2) , are apparently unable, after neonatal life, to produce sufficient erythropoietin to maintain the red cell mass at more than about 25% of the normal level (1). In patients with CRF, the amountof erythropoietin produced by the damaged kidneys and the extrarenal sites is sufficient to maintain a higher hematocrit than the anephric patients in whom erythropoietin is produced only by extrarenal sites (3) . This indicates that kidneys devoid of excretory function are still capable of producing a small but significant amount of erythropoietin. Two other factors have been implicated in the suppression of erythropoiesis in patients with CRF. The first is a decrease in the hemoglobin oxygen affinity which increases the efficiency of oxygen transport to the kidneys and therefore decreases the stimulus for erythropoietin production by anemia (4). This is caused by an increase in the 2-3 DPG content of the red cells relative to their pH. Since this phenomenon causes both a decrease in the red cell mass and an increase in the efficiency of oxygen transport, the net effect to the patient is probably not significant. Another factor, however, is the presence of inhibitors of erythropoiesis in the plasma of uremic patients (5) . These consist of low molecular weight substances which have been shown to inhibit heme synthesis, as well as CFU-E and BFU-E derived colony formation in-vitro. To date, there is no definitive data to suggest that these inhibitors influence erythropoiesis in-vivo. If this were the case, one would expect that administration of erythropoietin to uremic subjects would result in a smaller erythropoietic response than in non-uremic ones. Rats made uremic by subtotal nephrectomy respond to erythropoietin as well as do normal ones. However, the lack of erythropoietin suitable for human use has prevented the performance of definitive studies in patients. Now that purified erythropoietin is available the required data from this critical question will probably soon be available.
The red cell life span of uremic patients is moderately shortened to approximately half normal (1) . The causes of this are: 1) interference by substances in uremic plasma with the ability of erythrocytes to regulate their intracellular sodium content (7); 2) dysfunction of the pentose phosphate shunt system in erythrocytes of about 20% of uremic subjects (8); and 3) hypersplenism, which occurs, for unknown reasons, in some uremic patients on hemodialysis (9) . Microangiopathic hemolysis may contribute significantly to the severity of anemia in patients with CRF secondary to disease in the small blood vessels.
Aside from the above mentioned factors, which are related to uremia or to structural kidney damage, a variety of complications of the therapy of CRF can contribute to the anemia. These include:
1. Iron deficiency 2. Folate deficiency (10) 3. Excess hemolysis secondary to a) Hypophosphatemia from phosphate-binding-antacids b) Exposure to substances with a high oxidizing potential in patients with ,pentose phosphate shunt dysfunction c) Hypercuperemia due to copper leaking from tubes in the deionizing apparatus. 4. Anemias not directly caused by either renal. failure or its therapy (a particularly common anemia is the anemic of chronic illness) may also be present, and must be considered in the differential diagnosis of patients with CRF. At the present time there is no specific therapy available for the anemia of chronic renal failure. Effective hemodialysis, periodic monitoring of the serum ferritin and MCV to detect and treat iron deficiency, prophylactic administration of folates, and awareness of the correctible causes of excessive hemolysis have reduced the severity of anemia and thereby also reduced the symptoms of some patients with CRF. However, many patients remain sufficiently anemic to be symptomatic; and therefore require transfusion therapy. The available data is quite convincing that blood transfusions do not adversely effect the ability of a patient to accept a renalgraft, and may in fact be beneficial. Consequently the use of transfusion therapy is not as restricted as in the past. However, the risks of hepatitis and of sensitization to a variety of erythrocyte antigens still make it imperative that alternatives to transfusion therapy be discovered. The currently most effective means of reducing transfusion requirements in patients with CRF is by the use of androgen therapy. Androgenic steroids have been shown to increase the red cell mass of a variety of experimental animals and of man. One mechanism by which they do so is by increasing the amount of erythropoietin produced by the kidneys in response to any given stimulus (11, 12) . The effect of these compounds on erythropoietin production from extrarenal sites is not yet entirely clear. Rats, whose kidneys have been removed, respond poorly to the injection of androgens (2) . However, these experiments are not definitive in that the rats only survive 48-72 hours post-nephrectomy and because of their deteriorated condition 48 hours post-nephrectomy, all studies have been done within 24 hours of nephrectomy (2) . Anephric patients respond to injections of androgenic compounds to a variable extent (11, 13, 14) although in general they respond less well than do those with CRF but with kidneys in place. Androgenic compounds have also been shown to increase the responsiveness of erythroid progenitors to erythropoietin in-vitro (12) . The extent to which this mechanism influences erythropoiesis in-vivo is uncertain. Accordingly, the primary action of androgenic steroids is to enhance erythropoietin production by the diseased kidneys of patients with CRF and probably also, to some extent, by their external sites.
A variety of androgenic steroids have been shown to be effective including testosterone esters, fluoxymesterone (13) , and nortestosterone decandate (15) . Fluoxymesterone, a 17 methylated androstane has the advantage of being orally effective, but may be hepatotoxic, and consequently requires periodic monitoring of hepatic function. The nortestosterone compounds, because of their very high anabolic: androgenic ratio are the preferred compounds for use in females because of their minimal hirsutizing properties.
Cobaltous chloride has been used in the past to increase the RCM of patients with CRF. However, its use was discontinued because of excess toxicity. In recent years, there have been some favorable reports on the use of smaller less toxic doses of this compourids in treating the anemia of CRF (16). Now to move from what has been accomplished to the speculative. Purification of erythropoietin is now possible, albeit the amounts of this material that are available is limited (17) . One may, therefore, expect that definitive studies will soon be done to conclusively demonstrate whether or not one can stimulate eryt-hropoiesis in uremic patients , by injection of erythropoietin. If this is the case, then it is likely that more effort will be invested in developing methods to efficiently produce large quantities of erythropoietin for human use. This goal is not likely to be achieved in the near future, as its fulfillment still requires the resolution of some very complex technical problems.
Other lines of research which could conceivably result in unique methods of treating the anemia of CRF include the search for methods to increase extrarenal erythropoietin production, and the search for compounds that enhance erythropoiesis by a direct effect on erythroid precursor cells.
With regard to methods of enhancing extrarenal erythropoietin production, this can be accomplished in experimental animals by either infusion of large amounts of renin or angiotensin; or by causing liver injury (2) . It is of interest that patients with CRF that develop hepatitis have been reported to have an amelioration of their anemia during the period of active hepatitis (18) . Accordingly, one is encouraged by results of experiments in rodents that indicate the feasibility of substantially increasing extrarenal erythropoietin production. However, methods of doing this that would be clinically applicable have not yet been uncovered.
With regard to development of compounds which enhance erythropoiesis by a direct effect on erythroid precursors, a variety of compounds have been shown to enhance heme synthesis or erythroid colony formation in the presence of small amounts of erythropoietin in-vitro. These include 5~H metabolites of testosterone (12, 19) , calorigenic and non-calorigenic thiroxine ana loges (19, 20) dexamethasone (20) , and others. It remains to be determined whether these compounds will be effective in-vivo, or useful in treating the anemia of CRF.
In summary, progress has been made in delineating the various contributing factors in the pathogenesis of the anemia of CRF. Correction of those that have specific remedies, the use of androgenic steroids in patients that remain symptomatically anemic, and clarification of the hazards or lack thereof of transfusions in potential renal graft recipients has improved our ability to treat patients with the anemia of CRF more rationally and effectively. However, anemia remains the cause of substantial morbidity in a large number of patients with CRF. Hopefully one of the several avenues of research currently in progress will lead to more specific methods for treating the anemia of CRF.
